Showing results (1-10 of 50) with videos related to
Sort By:
Pageof 5
ACG Case Reports Journal|April 28, 2020
Behcet's Disease With Budd-Chiari Syndrome and Challenges in Its ManagementSudheer K Vuyyuru, Shivanand Gamanagatti, ShalimarCurrent Opinion in Gastroenterology|September 27, 2022
Considerations when starting patients on multiple biologics and small moleculesSudheer K Vuyyuru, Saurabh Kedia, Vineet AhujaACG Case Reports Journal|January 26, 2023
Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 StoneSudheer K Vuyyuru, Sarah A Morrow, Vipul JairathJGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 14, 2022
Immune-mediated inflammatory diseases of the gastrointestinal tract: Beyond Crohn's disease and ulcerative colitisSudheer K Vuyyuru, Saurabh Kedia, Pabitra Sahu, et al.Drugs|May 5, 2025
Differentiating IL-23 Inhibitors in Crohn's DiseaseOlga Maria Nardone, Sudheer K Vuyyuru, Yuhong Yuan, et al.The American Journal of Gastroenterology|July 6, 2023
Long Washout Periods Between Biologics for Inflammatory Bowel Disease Clinical Trials Are Unnecessary: A Canadian Retrospective Cohort StudySudheer K Vuyyuru, Meagan Archer, Tran M Nguyen, et al.Clinical Nutrition ESPEN|October 18, 2024
Association between nutritional status assessed by body mass index and Crohn's disease phenotype: A Nation-wide analysisJudwin Ndzo, Sudheer K Vuyyuru, Thomas Trimble, et al.Digestive Diseases and Sciences|November 14, 2019
A Randomized Control Trial of Thromboelastography-Guided Transfusion in Cirrhosis for High-Risk Invasive Liver-Related ProceduresSudheer K Vuyyuru, Achintya D Singh, Shivanand R Gamanagatti, et al.Drugs|June 2, 2023
Targeting IL-23 for IBD: Rationale and Progress to DateSudheer K Vuyyuru, Lisa M Shackelton, Jurij Hanzel, et al.Therapeutic Advances in Gastroenterology|February 25, 2025
Artificial intelligence to revolutionize IBD clinical trials: a comprehensive reviewRocio Sedano, Virginia Solitano, Sudheer K Vuyyuru, et al.Pageof 5